Medtronic, Inc.

Other

Medronic, Inc.

Medtronic, Inc. (cvg)

Troy Edward Jackson

Mark L Brown

Xusheng Zhang

Jeffrey M Gillberg

Saul E Greenhut

Paul A Belk

Wade M Demmer

Walter H Olson

Robert J Nehls

James D Reinke

Teresa A Whitman

Vincent P Ganion

Robert W Stadler

Paul R Solheim

Raja N Ghanem

Yanina Grinberg

Karen J Kleckner

Jian L Cao

Bruce D Gunderson

Vinod Sharma

Vladimir Pavlovich Nikolski

Timothy A Ebeling

Maneesh Shrivastav

Benjamin P Rhodes

Sandra B Charlton

Arun Kumar

Todd Jon Sheldon

Subham Ghosh

Andrew J Ries

Catherine R Condie

Robert A Betzold

Michael F Hess

John Charles Stroebel

Paul J Degroot

Lilian Kornet

Richard N Cornelussen

Jonathan D Edmonson

James H Ericksen

Yuanzhen Liu

Irving J Sanchez

Shravya Srigiri

Alfonso Aranda Hernandez

Joseph S Leak, Sr

Kevin L Dehmer

James A Vander Heyden

Richard Cornelussen

Karin J Kleckner

An extra-cardiovascular implantable cardioverter defibrillator (ICD) system receives a cardiac electrical signal by an electrical sensing circuit via an extra-cardiovascular sensing electrode vector and senses cardiac events from the cardiac electrical signal. The ICD system detects tachycardia from the cardiac electrical signal and determines a tachycardia cycle length from the cardiac electrical signal. The ICD system determines an ATP interval based on the tachycardia cycle length and sets an extended ATP interval that is longer than the ATP interval. The ICD delivers ATP pulses to a patient's heart via an extra-cardiovascular pacing electrode vector different than the sensing electrode vector. The ATP pulses include a leading ATP pulse delivered at the extended ATP interval after a cardiac event is sensed from the cardiac electrical signal and a second ATP pulse delivered at the ATP interval following the leading ATP pulse.

Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system

A medical device is configured to sense a cardiac electrical signal and detect an atrial tachyarrhythmia based on the sensed cardiac electrical signal. The medical device is configured to determine that far field oversensing criteria are met by the cardiac electrical signal during the detected atrial tachyarrhythmia. The medical device may detect termination of the detected atrial tachyarrhythmia in response to the far field oversensing criteria being met.

Device and method for atrial tachyarrhythmia detection

A medical device comprises therapy delivery circuitry and processing circuitry. The therapy delivery circuitry is configured to deliver anti-tachycardia pacing (ATP) therapy to a heart of a patient. The ATP therapy includes one or more pulse trains and each of the one or more pulse trains includes a plurality of pacing pulses. The processing circuitry is configured to, for at least one of the plurality of pacing pulses of at least one of the one or more pulse trains, determine at least one latency metric of an evoked response of the heart to the pacing pulse. The processing circuitry is further configured to modify the ATP therapy based on the at least one latency metric.

Latency-based adaptation of anti-tachyarrhythmia pacing therapy

A method and device apparatus to deliver a pacing therapy capable of remodeling a patient's heart over a period of time that includes monitoring one or more parameters in response to a delivered cardiac remodeling pacing, determining whether the cardiac remodeling pacing has an effect on cardiac normalization in response to the monitoring, and adjusting the cardiac remodeling pacing in response to the determined effect on cardiac normalization. The method and device may also perform short-term monitoring of one or more parameters in response to the delivered cardiac remodeling pacing, monitor one or more long-term parameter indicative of a long-term effect of the delivered cardiac remodeling pacing, determine the long-term effect of the delivered cardiac remodeling pacing on cardiac normalization in response to the monitoring, and adjust the cardiac remodeling pacing in response to one or both of the short-term monitoring and the determined long-term effect on cardiac normalization.

Delivery of cardiac pacing therapy for cardiac remodeling

A method of operating an implantable blood pump and a pacing device, the method includes determining an end diastolic volume (EDV) and ejection fraction of one from the group consisting of the right ventricle and the left ventricle at a predetermined pump set speed. An average flow rate based on the predetermined pump set speed is determined. A target heart rate based at least in part on the determined EDV, ejection fraction, and average flow rate is determined. A lower rate for the pacing device is determined, the pacing device being in electrical communication with a chamber of the heart. The chamber of the heart is paced when a measured heart rate drops below the lower rate.

Ventricular geometric and hemodynamic control by heart rate modulation in LVAD therapy

Techniques and systems for monitoring cardiac arrhythmias and delivering electrical stimulation therapy using a subcutaneous implantable cardioverter defibrillator (SICD) and a leadless pacing device (LPD) are described. For example, the SICD may detect a tachyarrhythmia within a first electrical signal from a heart and determine, based on the tachyarrhythmia, to deliver anti-tachyarrhythmia shock therapy to the patient to treat the detected arrhythmia. The LPD may receive communication from the SICD requesting the LPD deliver anti-tachycardia pacing to the heart and determine, based on a second electrical signal from the heart sensed by the LPD, whether to deliver anti-tachycardia pacing (ATP) to the heart. In this manner, the SICD and LPD may communicate to coordinate ATP and/or cardioversion/defibrillation therapy. In another example, the LPD may be configured to deliver post-shock pacing after detecting delivery of anti-tachyarrhythmia shock therapy.

Systems and methods for leadless pacing and shock therapy

An example medical device system includes therapy delivery circuitry configured to deliver anti-tachycardia pacing (ATP) therapy to a heart of a patient via electrodes communicatively coupled to the therapy delivery circuitry. The ATP therapy includes one or more ATP trains. The medical device system also includes processing circuitry configured determine a first propagation time based on a comparison of features in a local electrogram and a far-field electrogram, such as the time from a fiducial point in the local electrogram and QRS onset in the far-field electrogram. The processing circuitry is also configured to determine, based on the first propagation time, a number of pulses to achieve a second propagation time and control the therapy delivery circuitry to deliver the ATP train of at least the number of pulses.

Guiding anti-tachyarrhythmia pacing train design and electrode selection with electrograms

A method for heart failure management includes monitoring one or more sensor-based parameters for a patient to determine a pacing therapy. If the one or more parameters indicate atrial tachycardia or atrial fibrillation, a first pacing therapy is delivered. If the one or more parameters do not indicate atrial tachycardia or atrial fibrillation, it is determined whether the patient is asleep. If the patient is asleep, a second pacing therapy is delivered. If the one or more parameters do not indicate atrial tachycardia, atrial fibrillation, or that the patient is asleep, the patient's P-wave duration is evaluated with respect to a P-wave duration threshold value. When the patient's P-wave duration is determined to exceed the P-wave duration threshold value, a third pacing therapy is delivered, and when the patient's P-wave duration is determined to not exceed the P-wave duration threshold value, a fourth pacing therapy is delivered.

Pacing therapy selection for heart failure treatment

A medical device is configured to determine time intervals between consecutive cardiac events sensed from a cardiac electrical signal, increase a value of a tachyarrhythmia interval count in response to each of the determine time intervals detected as a tachyarrhythmia interval. The device is further configured to detect normal sinus rhythm events and the decrease the value of the tachyarrhythmia interval count in response to a threshold number of detected normal sinus rhythm events.

Medical device and method for tachyarrythmia detection

An implantable medical device includes an electrically conductive first housing, a conductive feedthrough extending through the first housing, electronic circuitry positioned within the first housing, a device electrode, and a second housing. The electronic circuitry is electrically coupled to the first housing and the feedthrough, and senses electrical signals of a patient and/or delivers electrical stimulation therapy to the patient via the first housing and the feedthrough. The device electrode is configured to electrically connect with tissue and/or a fluid at a target site in the patient. A lead connector is configured to connect to a proximal end of an implantable medical lead. The lead connector includes a first connector contact electrically coupled to the feedthrough and a second connector contact electrically coupled to the first housing.

Cardiac pacing device with mechanical mode switching

An implantable medical device system is configured to detect a tachyarrhythmia from a cardiac electrical signal and start an ATP therapy delay period. The implantable medical device determines whether the cardiac electrical signal received during the ATP therapy delay period satisfies ATP delivery criteria. A therapy delivery module is controlled to cancel the delayed ATP therapy if the ATP delivery criteria are not met and deliver the delayed ATP therapy if the ATP delivery criteria are met.

Anti-tachycardia pacing control in an implantable medical device system

A method includes determining that a patient has heart failure with preserved ejection fraction (HFpEF); configuring a cardiovascular (CV) model using patient characterization data; determining one or more therapy parameters using output data of the CV model; and administering HFpEF therapy based on the one or more therapy parameters.

Model-based therapy parameters for heart failure

Systems and methods are described herein for evaluation and adjustment of a left ventricular assist device (LVAD). The systems and methods may utilize at least a plurality of external electrodes to monitor cardiac electrical activity before and during LVAD therapy. The cardiac electrical activity as well as other information such cardiac sound information may be used to determine and adjust one or more LVAD output parameters such as pump speed.

Left ventricular assist device adjustment and evaluation

Growing community of inventors

New Brighton, MN, United States of America

Troy Edward Jackson